LEXX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (20 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	343 955
Średni wolumen	478 383
Kapitalizacja rynkowa	37.63M
EPS	$0 ( 2024-04-12 )
Następna data zysków	( $-0.130 ) 2024-07-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.36
ATR14	$0.0280 (0.96%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-14	Carle Vanessa	Sell	2 500	Stock Options
2024-05-14	Carle Vanessa	Buy	2 500	common shares
2024-04-26	Carle Vanessa	Buy	10 000	Stock Options
2024-04-26	Turkel Catherine C.	Buy	5 000	Stock Options
2024-04-26	Baxter Nicholas W	Buy	5 000	Stock Options

INSIDER POWER
10.87
Last 99 transactions
Buy: 3 496 310 \| Sell: 1 994 235

Wolumen Korelacja

Długi: -0.01 (neutral)

Krótki: 0.27 (neutral)

Signal:(48.242) Neutral

Lexaria Bioscience Corp. Korelacja

10 Najbardziej pozytywne korelacje
AIHS	0.867
PASG	0.86
POWL	0.856
SLN	0.856
VTYX	0.856
CLBT	0.851
MRUS	0.85
KYMR	0.85
PEPG	0.847
QRTEP	0.845

10 Najbardziej negatywne korelacje
MDRX	-0.823
DPRO	-0.816

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Lexaria Bioscience Corp. Korelacja - Waluta/Towar

-0.15
( neutral )

0.28
( neutral )

0.00
( neutral )

0.19
( neutral )

0.77
( moderate )

-0.38
( neutral )

Lexaria Bioscience Corp. Finanse

Annual	2023
Przychody:	$226 208
Zysk brutto:	$194 708 (86.07 %)
EPS:	$-1.010

FY	2023
Przychody:	$226 208
Zysk brutto:	$194 708 (86.07 %)
EPS:	$-1.010

FY	2022
Przychody:	$255 397
Zysk brutto:	$183 556 (71.87 %)
EPS:	$-1.240

FY	2021
Przychody:	$722 738
Zysk brutto:	$547 392 (75.74 %)
EPS:	$-0.950

Financial Reports:

No articles found.

Lexaria Bioscience Corp. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Lexaria Bioscience Corp.

Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.